Childhood Cancer Incidence, New York State, 2014-2018

Source: New York State Cancer Registry

Site of Cancer Ages 0-4 Ages 5-9 Ages 10-14 Ages 15-19 Combined Ages 0-14 Combined Ages 0-19
Avg Annual Cases Rate per 1,000,000 Avg Annual Cases Rate per 1,000,000 Avg Annual Cases Rate per 1,000,000 Avg Annual Cases Rate per 1,000,000 Avg Annual Cases Rate per 1,000,000 95% CI Avg Annual Cases Rate per 1,000,000 95% CI
All Invasive Malignant Tumors 290.8 249.6 161.6 143.3 214.2 187.8 346.4 284.2 666.6 192.6 186.1-199.2 1013.0 215.6 209.7-221.7
I Leukemias 94.8 81.4 47.0 41.7 39.2 34.4 52.0 42.7 181.0 52.0 48.6-55.5 233.0 49.6 46.8-52.6
   I(a) Lymphoid leukemias 67.4 57.8 37.2 33.0 22.8 20.0 23.8 19.5 127.4 36.6 33.8-39.6 151.2 32.3 30.0-34.7
   I(b) Acute myeloid leukemia 15.4 13.2 4.2 3.7 8.6 7.5 16.0 13.1 28.2 8.1 6.8-9.5 44.2 9.3 8.2-10.7
II Lymphomas and reticuloendothelial neoplasms 21.8 18.7 22.4 19.9 43.4 38.1 80.6 66.1 87.6 25.7 23.3-28.2 168.2 35.8 33.5-38.4
   II(a) Hodgkin lymphoma 0.8 0.7 2.6 2.3 18.4 16.1 50.0 41.0 21.8 6.5 5.3-7.8 71.8 15.2 13.6-16.8
   II(b,c,d) Non-Hodgkin lymphomas 20.8 17.8 19.8 17.6 24.8 21.7 29.4 24.1 65.4 19.1 17.1-21.2 94.8 20.3 18.5-22.3
III CNS & misc intracranial & intraspinal neoplasms 57.6 49.4 43.6 38.7 41.0 35.9 30.2 24.8 142.2 41.2 38.2-44.4 172.4 37.1 34.6-39.6
   III(a) Ependymomas and choroid plexus tumor 6.4 5.5 3.4 3.0 2.8 2.5 3.0 2.5 12.6 3.6 2.8-4.6 15.6 3.3 2.6-4.2
   III(b) Astrocytoma 31.8 27.3 24.8 22.0 24.0 21.0 16.2 13.3 80.6 23.4 21.2-25.8 96.8 20.8 19.0-22.8
   III(c) Intracranial and intraspinal embryonal tum 12.0 10.3 6.8 6.0 3.8 3.3 2.6 2.1 22.6 6.5 5.3-7.8 25.2 5.4 4.5-6.4
   III(d) Other gliomas 5.2 4.5 7.4 6.6 8.6 7.5 6.8 5.6 21.2 6.2 5.1-7.5 28.0 6.1 5.1-7.2
IV Neuroblastoma and other peripheral nervous cell tumors 36.4 31.2 6.8 6.0 1.0 0.9 2.0 1.6 44.2 12.4 10.8-14.1 46.2 9.7 8.5-11.0
   IV(a) Neuroblastoma and ganglioneuroblastoma 36.4 31.2 6.8 6.0 1.0 0.9 1.0 0.8 44.2 12.4 10.8-14.1 45.2 9.5 8.3-10.8
V Retinoblastoma 15.4 13.2 0.4 0.4 0.2 0.2 0.2 0.2 16.0 4.4 3.5-5.5 16.2 3.3 2.7-4.2
VI Renal tumors 24.0 20.6 7.8 6.9 3.0 2.6 1.4 1.1 34.8 9.9 8.5-11.4 36.2 7.7 6.6-8.9
   VI(a) Nephroblastoma and other nonepithelial rena 24.0 20.6 7.6 6.7 1.0 0.9 0.0 0.0 32.6 9.2 7.8-10.7 32.6 6.9 5.9-8.0
VII Hepatic tumors 8.2 7.0 1.2 1.1 0.8 0.7 2.6 2.1 10.2 2.9 2.1-3.8 12.8 2.7 2.1-3.4
   VII(a) Hepatoblastoma 7.8 6.7 1.0 0.9 0.2 0.2 0.0 0.0 9.0 2.5 1.8-3.4 9.0 1.9 1.4-2.5
VIII Malignant bone tumors 2.2 1.9 7.6 6.7 22.4 19.6 22.2 18.2 32.2 9.6 8.1-11.2 54.4 11.7 10.4-13.2
   VIII(a) Osteosarcoma 0.2 0.2 3.0 2.7 14.8 13.0 12.0 9.8 18.0 5.4 4.3-6.6 30.0 6.5 5.5-7.6
   VIII(c) Ewing tumor and related sarcomas of bone 1.4 1.2 4.0 3.5 5.4 4.7 6.0 4.9 10.8 3.2 2.4-4.2 16.8 3.6 2.9-4.5
IX Soft tissue and other extraosseous sarcomas 15.4 13.2 12.4 11.0 17.4 15.3 23.6 19.4 45.2 13.2 11.5-15.0 68.8 14.7 13.2-16.4
   IX(a) Rhabdomyosarcoma 10.4 8.9 5.8 5.1 4.4 3.9 5.4 4.4 20.6 5.9 4.8-7.2 26.0 5.5 4.6-6.6
X Germ cell & trophoblastic tumors & gonadal neoplasms 8.2 7.0 5.0 4.4 12.2 10.7 31.4 25.8 25.4 7.4 6.2-8.8 56.8 12.0 10.7-13.5
   X(a) Intracranial and intraspinal germ cell tumo 0.6 0.5 1.2 1.1 4.2 3.7 2.6 2.1 6.0 1.8 1.2-2.5 8.6 1.9 1.4-2.5
   X(c) Malignant gonadal germ cell tumor 1.6 1.4 3.4 3.0 7.8 6.8 24.0 19.7 12.8 3.8 2.9-4.8 36.8 7.8 6.7-9.0
XI Other malignant epithelial neoplasms and malignant melanomas 2.6 2.2 5.8 5.1 31.8 27.9 98.0 80.4 40.2 11.9 10.3-13.7 138.2 29.2 27.0-31.4
   XI(b) Thyroid carcinoma 0.4 0.3 1.8 1.6 14.8 13.0 58.4 47.9 17.0 5.1 4.0-6.3 75.4 15.8 14.3-17.5
   XI(d) Malignant melanoma 1.6 1.4 1.0 0.9 1.8 1.6 8.0 6.6 4.4 1.3 0.8-1.9 12.4 2.6 2.0-3.3
XII Other and unspecified malignant neoplasms 2.2 1.9 0.6 0.5 0.8 0.7 1.8 1.5 3.6 1.0 0.6-1.6 5.4 1.1 0.8-1.7

Notes

  • Incidence data are provisional, November 2020.
  • Rates are per 1,000,000 children. Rates for 0-14 and 0-19 year age intervals are age-adjusted within these intervals to the 2000 US standard population, with 95% confidence intervals.
  • Rates based on fewer than 4 cases per year are unstable and should be used with caution.
  • Non-Hodgkin lymphomas, Burkitt, and miscellaneous lymphomas are grouped together under II(b,c,d).